Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting
cognition, function, and behavior. Alzheimer's disease progresses along a continuum from …

Positron emission tomography (PET) constitutes a functional imaging technique that is
harnessed to probe biological processes in vivo. PET imaging has been used to diagnose …

Noncancerous diseases include a wide plethora of medical conditions beyond cancer and
are a major cause of mortality around the world. Despite progresses in clinical research …

Neurological and psychiatric diseases have high degrees of genetic and pathophysiological
heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have …

Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are
no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available …

Brain aging is a complex process that affects everything from the subcellular to the organ
level, begins early in life, and accelerates with age. Morphologically, brain aging is primarily …

Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised
questions about their preferential association with the hallmark pathologies of Alzheimer …

Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that
tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (A β). We …